NASDAQ:EDSA - Edesa Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 80.83 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$5.53
▲ +0.01 (0.18%)
1 month | 3 months | 12 months
Get New Edesa Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDSA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$10.00
▲ +80.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Edesa Biotech in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 80.83% upside from the last price of $5.53.
Buy
The current consensus among 1 polled investment analysts is to buy stock in Edesa Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/30/2020Brookline Capital ManagementInitiated CoverageBuy$10.00High
i
Rating by K. Raja at Brookline Capital Management
(Data available from 3/1/2016 forward)
Edesa Biotech logo
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Read More

Today's Range

Now: $5.53
$5.43
$5.66

50 Day Range

MA: $6.11
$4.84
$7.48

52 Week Range

Now: $5.53
$1.58
$19.10

Volume

2,248 shs

Average Volume

897,221 shs

Market Capitalization

$61.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Edesa Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Edesa Biotech in the last twelve months: Brookline Capital Management.
View the latest analyst ratings for EDSA.

What is the current price target for Edesa Biotech?

1 Wall Street analysts have set twelve-month price targets for Edesa Biotech in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 81.2%. Brookline Capital Management has the highest price target set, predicting EDSA will reach $10.00 in the next twelve months. Brookline Capital Management has the lowest price target set, forecasting a price of $10.00 for Edesa Biotech in the next year.
View the latest price targets for EDSA.

What is the current consensus analyst rating for Edesa Biotech?

Edesa Biotech currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EDSA will outperform the market and that investors should add to their positions of Edesa Biotech.
View the latest ratings for EDSA.

What other companies compete with Edesa Biotech?

How do I contact Edesa Biotech's investor relations team?

Edesa Biotech's physical mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company's listed phone number is 289-800-9600 and its investor relations email address is [email protected] The official website for Edesa Biotech is www.edesabiotech.com.